Intraoperative hydroxyethyl starch 70/0.5 is not related to acute kidney injury in surgical patients: Retrospective cohort study

Anesthesia and Analgesia

Volumn 115, Issue 6, 2012, Pages 1309-1314

  Endo, Arata ^a   Uchino, Shigehiko ^a   Iwai, Kennichi ^a   Saito, Keita ^a   Sanui, Masamitsu ^a   Takinami, Masanori ^a   Uezono, Shoichi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; HETASTARCH;

ACUTE KIDNEY FAILURE; ADULT; AGED; ARTICLE; BLEEDING; CLINICAL ASSESSMENT TOOL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PEROPERATIVE CARE; PEROPERATIVE COMPLICATION; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURGICAL PATIENT; UNIVERSITY HOSPITAL;

ACUTE KIDNEY INJURY; AGED; AGED, 80 AND OVER; BLOOD LOSS, SURGICAL; COHORT STUDIES; FEMALE; HOSPITAL MORTALITY; HUMANS; HYDROXYETHYL STARCH DERIVATIVES; JAPAN; KIDNEY FAILURE, CHRONIC; LOGISTIC MODELS; MALE; MIDDLE AGED; PLASMA SUBSTITUTES; RETROSPECTIVE STUDIES; SURGICAL PROCEDURES, OPERATIVE; TREATMENT OUTCOME;

EID: 84870244274     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/ANE.0b013e31826ba8d7     Document Type: Article

References (27)

1. Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H. Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 1993;342:248-9
2. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 1996;348:1620-2
3. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S, Olthoff D, Jaschinski U, John S, Rossaint R, Welte T, Schaefer M, Kern P, Kuhnt E, Kiehntopf M, Hartog C, Natanson C, Loeffer M, Reinhart K. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med 2008;358:125-39
4. Rioux J P, Lessard M, De Bortoli B, Roy P, Albert M, Verdant C, Madore F, Troyanov S. Pentastarch 10% (250 kDa/0.45) is an independent risk factor of acute kidney injury following cardiac surgery. Crit Care Med 2009;37:1293-8
5. de Jonge E, Levi M. Effects of different plasma substitutes on blood coagulation: a comparative review. Crit Care Med 2001;29:1261-7
6. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, Brochard L. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet 2001;357:911-6
7. Schortgen F, Girou E, Deye N, Brochard L; CRYCO Study Group. The risk associated with hyperoncotic colloids in patients with shock. Intensive Care Med 2008;34:2157-68
8. Bayer O, Reinhart K, Sakr Y, Kabisch B, Kohl M, Riedemann NC, Bauer M, Settmacher U, Hekmat K, Hartog CS. Renal effects of synthetic colloids and crystalloids in patients with severe sepsis: a prospective sequential comparison. Crit Care Med 2011;39:1335-42
9. Jungheinrich C, Sauermann W, Bepperling F, Vogt NH. Volume effcacy and reduced infuence on measures of coagulation using hydroxyethyl starch 130/0.4 (6%) with an optimised in vivo molecular weight in orthopaedic surgery: a randomised, double-blind study. Drugs R D 2004;5:1-9
10. Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R, Miller D, Shangraw RE, Prough DS, Baus D, Bepperling F, Warltier DC. Volume replacement therapy during major orthopedic surgery using Voluven® (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology 2007;106:1120-7
11. Hartog CS, Kohl M, Reinhart K. A systematic review of third-generation hydroxyethyl starch (HES 130/0.4) in resuscitation: safety not adequately addressed. Anesth Analg 2011; 112:635-45
12. Gattas DJ, Dan A, Myburgh J, Billot L, Lo S, Finfer S; CHEST Management Committee. Fluid Resuscitation with 6% hydroxy-ethyl starch (130/0.4) in acutely ill patients: an updated systematic review and meta-analysis. Anesth Analg 2011;114:159-69
13. Hartog C, Reinhart K. CONTRA: hydroxyethyl starch solutions are unsafe in critically ill patients. Intensive Care Med 2009;35:1337-42
14. Dart AB, Mutter TC, Ruth CA, Taback SP. Hydroxyethyl starch (HES) versus other fuid therapies: effects on kidney function. Cochrane Database Syst Rev 2010;1:CD007594
15. Suzuki T, Miyao H, Terui K, Koyama K, Shiibashi M. Fluid therapy with hydroxyethyl starch for massive blood loss during surgery. J Anesth 2010;24:418-25
16. Imai E, Horio M, Nitta K, Yamagata K, Iseki K, Tsukamoto Y, Ito S, Makino H, Hishida A, Matsuo S. Modifcation of the Modifcation of Diet in Renal Disease (MDRD) Study equation for Japan. Am J Kidney Dis 2007;50:927-37
17. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure: defnition, outcome measures, animal models, fuid therapy and information technology needs-the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-12
18. Beattie WS, Karkouti K, Wijeysundera DN, Tait G. Risk associated with preoperative anemia in noncardiac surgery: a single-center cohort study. Anesthesiology 2009;110:574-81
19. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998;17:2265-81
20. Schortgen F, Deye N, Brochard L. Preferred plasma volume expanders for critically ill patients: results of an international survey. Intensive Care Med 2004;30:2222-9
21. Finfer S, Liu B, Taylor C, Bellomo R, Billot L, Cook D, Du B, McArthur C, Myburgh J; SAFE TRIPS Investigators. Resuscitation fuid use in critically ill adults: an international cross sectional study in 391 intensive care units. Crit Care 2010;14:R185
22. Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products-different effects. Anesthesiology 2009;111:187-202
23. Mahmood A, Gosling P, Vohra RK. Randomized clinical trial comparing the effects on renal function of hydroxyethyl starch or gelatine during aortic aneurysm surgery. Br J Surg 2007;94:427-33
24. Godet G, Lehot JJ, Janvier G, Steib A, De Castro V, Coriat P. Safety of HES 130/0.4 (Voluven®) in patients with preoperative renal dysfunction undergoing abdominal aortic surgery: a prospective, randomized, controlled, parallel-group multicentre trial. Eur J Anaesthesiol 2008;25:986-94
25. Mukhtar A, Aboulfetouh F, Obayah G, Salah M, Emam M, Khater Y, Akram R, Hoballah A, Bahaa M, Elmeteini M, Hamza A. The safety of modern hydroxyethyl starch in living donor liver transplantation: a comparison with human albumin. Anesth Analg 2009;109:924-30
26. Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, Åneman A, Madsen KR, Møller MH, Elkjær JM, Poulsen LM, Bendtsen A, Winding R, Steensen M, Berezowicz P, Sø e-Jensen P, Bestle M, Strand K, Wiis J, White JO, Thornberg KJ, Quist L, Nielsen J, Andersen LH, Holst LB, Thormar K, Kjældgaard AL, Fabritius ML, Mondrup F, Pott FC, Møller TP, Winkel P, Wetterslev J; 6S Trial Group; Scandinavian Critical Care Trials Group. Hydroxyethyl starch 130/0.42 versus Ringer's acetate in severe sepsis. N Engl J Med 2012;367:124-34
27. Dexter F, Dexter EU, Ledolter J. Importance of appropriately modeling procedure and duration in logistic regression studies of perioperative morbidity and mortality. Anesth Analg 2011;113:1197-201